| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1197.0B | ¥1133.9B | +5.6% |
| Operating Income | ¥89.2B | ¥83.7B | +6.6% |
| Ordinary Income | ¥100.0B | ¥85.9B | +16.4% |
| Net Income | ¥72.8B | ¥60.4B | +22.9% |
| ROE | 7.1% | 6.0% | - |
FY2025 Q3 results demonstrate steady growth with revenue reaching 119.7 billion yen (YoY +5.6%), Operating Income of 8.9 billion yen (+6.6%), Ordinary Income of 10.0 billion yen (+16.4%), and Net Income attributable to owners of 7.3 billion yen (+20.5%). The company achieved both top-line expansion and profitability improvement across most segments, with particularly strong performance in Industrial Infrastructure and Electronic Materials segments. Operating margin improved to 7.5%, while ordinary income growth significantly outpaced operating income growth, indicating contribution from non-operating items including foreign exchange gains and interest income. The company maintains solid financial health with equity ratio of 65.1% and current ratio of 194.2%, though notable balance sheet changes include a substantial increase in short-term borrowings and continued accumulation of construction in progress.
Revenue growth of 5.6% was driven primarily by the Industrial Infrastructure segment (sales +10.7%) and Electronic Materials segment (sales +5.2%). Industrial Infrastructure benefited from robust demand in HVAC piping and chimney construction projects, as well as increased sales of adhesive products for automotive films. Electronic Materials captured growth in AI-related semiconductor markets, with information recording materials showing significant revenue expansion. Environmental Solutions segment grew modestly at 0.9%, offsetting the divestiture impact of food packaging business through growth in refill packaging. Wellness segment increased 4.8% on steady domestic and overseas pharmaceutical/medical demand and Q3 recovery in bioprocessing single-use bags.
Operating income increased 6.6%, outpacing revenue growth and demonstrating operating leverage. The improvement was concentrated in Industrial Infrastructure (operating income +17.6% to 3.9 billion yen, margin 12.7%) and Electronic Materials (operating income +12.2% to 3.7 billion yen, margin 8.8%). These gains were partially offset by significant profit decline in Wellness segment (operating income -69.8% to 0.2 billion yen, margin 0.8%), primarily due to increased depreciation from the new Mie facility and upfront investment costs for bioprocessing bag expansion.
Ordinary income increased 16.4%, substantially exceeding operating income growth. This gap of 9.8 percentage points indicates meaningful contribution from non-operating items, specifically foreign exchange gains and interest income as noted in presentation materials. The company recognized favorable FX effects and interest receipts that boosted profitability beyond core operating performance.
Net income grew 20.5% to 7.3 billion yen, with net profit margin improving to 6.1% from 5.3%. The acceleration from ordinary income (+16.4%) to net income (+20.5%) suggests favorable tax effects or lower extraordinary losses compared to prior year. No material extraordinary items were flagged in available disclosures.
This represents a revenue up/profit up pattern with profit growth exceeding revenue growth, indicating improving operational efficiency and positive operating leverage, though with material support from non-operating items.
Industrial Infrastructure is the core business by operating profit contribution, generating 3.9 billion yen in operating income (44.0% of total segment operating profit) on sales of 32.3 billion yen. This segment delivered both the highest profit margin (12.7%) and strongest growth rate (operating income +17.6%). Architectural materials division showed robust performance in HVAC piping, void slabs, and chimney construction projects. Chemical products division increased sales of adhesive products for automotive films both domestically and in China. The segment drove overall profit growth despite representing 26.5% of total revenue.
Electronic Materials generated 4.3 billion yen in operating income (41.8% of segment total) on sales of 43.4 billion yen, with operating margin of 8.8%. Operating profit increased 12.2% as information recording materials captured significant growth from AI-related semiconductor demand. Display-related products showed strength in domestic markets, though Taiwan subsidiary faced production challenges. This segment's margin improvement from prior year contributed meaningfully to overall profitability enhancement.
Environmental Solutions produced 1.1 billion yen in operating income (12.1% of segment total) on sales of 26.2 billion yen, with operating margin of 4.3%. Operating profit declined marginally (-2.4%) due to profitability issues at the US subsidiary despite overall revenue growth of 0.9%. Living packaging division offset food packaging business divestiture through growth in refill and cosmetic packaging. Liquid container division faced challenges with US operations and changes in delivery formats to customers.
Wellness segment generated 0.2 billion yen in operating income (2.0% of segment total) on sales of 21.5 billion yen, with operating margin compressed to 0.8%. Operating profit declined sharply (-69.8%) despite 4.8% revenue growth. The profit compression stems from increased depreciation expense (estimated 1.9 billion yen annually from new Mie facility) and upfront investment in development and commercialization of bioprocessing single-use bags. Pharmaceutical and medical-related products maintained steady domestic and overseas demand, while bioprocessing products showed Q3 recovery.
Segment margin variance is substantial, ranging from 12.7% (Industrial Infrastructure) to 0.8% (Wellness). Industrial Infrastructure's superior margin reflects favorable construction project mix and high-margin chemical products, while Wellness segment's compression is temporary, driven by capacity expansion and pre-commercialization investment rather than demand weakness.
Profitability: ROE 6.4% (improved from prior year, calculated as net income margin 5.4% × asset turnover 0.763 × financial leverage 1.54), Operating Margin 7.5% (improved from 7.4% prior year), Net Profit Margin 6.1% (improved from 5.3%), EBIT Margin 7.5%
Cash Quality: Operating CF data not disclosed in XBRL, limiting assessment of cash conversion. Contract liabilities of 5.0 billion yen indicate advance customer payments. Receivables turnover at 117 days signals extended collection periods warranting monitoring.
Investment: CapEx and D&A details not available in XBRL data. Presentation materials indicate full-year CapEx forecast of 18.9 billion yen. Construction in progress of 14.5 billion yen (9.2% of total assets) reflects ongoing facility investments, particularly the Mie facility for Wellness segment.
Financial Health: Equity Ratio 65.1% (prior 65.4%), Current Ratio 194.2%, Quick Ratio 174.4%, Interest-bearing Debt 9.0 billion yen, Cash and Deposits 16.9 billion yen indicating net cash position, Interest Coverage Ratio 58.7x demonstrates ample interest payment capacity.
Efficiency: Asset Turnover 0.763, Total Asset 156.9 billion yen (prior 153.9 billion yen), Financial Leverage 1.54x.
Operating CF data is not disclosed in the available XBRL financial statements, preventing calculation of OCF/Net Income ratio and direct assessment of cash generation quality. The absence of operating cash flow disclosure limits visibility into actual cash conversion of reported earnings.
Investing CF details are not available in XBRL data. Presentation materials indicate planned full-year CapEx of 18.9 billion yen for FY2025, focused on Wellness segment capacity expansion (Mie facility) and other facility investments. Construction in progress balance of 14.5 billion yen represents 9.2% of total assets, suggesting significant ongoing capital deployment.
Financing CF information is not disclosed in XBRL. Presentation materials indicate dividend payments of 18 yen per share at interim and 18 yen planned for year-end (total 36 yen annually). Share buyback program was resolved in November 2025 with maximum of 1.82 million shares or 2.0 billion yen through June 2026; as of January 2026, 813,200 shares had been acquired.
FCF cannot be calculated due to lack of operating and investing cash flow disclosure.
Cash generation assessment: Cannot be definitively rated as strong, adequate, or needs monitoring without operating cash flow data. However, the company maintains a net cash position (cash 16.9 billion yen vs. interest-bearing debt 9.0 billion yen) and strong current ratio (194.2%), suggesting adequate liquidity. Accounts receivable days of 117 indicate slower collection requiring monitoring. The significant construction in progress balance suggests material cash has been deployed in facility investments with future returns pending.
Ordinary vs Net Income: Ordinary income of 10.0 billion yen exceeded operating income of 8.9 billion yen by 1.1 billion yen (+12.4%), driven by non-operating income including foreign exchange gains and interest income as noted in presentation materials. This represents approximately 0.9% of revenue and indicates moderate contribution from non-operating items. The gap is not material enough to raise concerns but does indicate that profit growth benefited from favorable FX and financial income beyond core operations.
Net income of 7.3 billion yen compared to ordinary income of 10.0 billion yen yields an effective tax burden of approximately 27%. The progression from ordinary to net income appears normal without material extraordinary items disclosed.
Non-operating income contribution: Non-operating income of approximately 1.1 billion yen represents 0.9% of revenue, below the 5% materiality threshold. However, as noted, this contributed meaningfully to the gap between operating income growth (+6.6%) and ordinary income growth (+16.4%). FX gains are inherently volatile and should not be viewed as recurring.
Accruals and Cash Quality: Operating cash flow data is not available, preventing assessment of whether OCF trails net income. The extended accounts receivable collection period (117 days) suggests potential accruals concerns, as revenue recognition may be outpacing cash collection. This represents an earnings quality watch item pending future cash flow disclosure.
Overall earnings quality is solid on an accrual basis with operating profit improvement driven by volume growth and margin expansion in core segments. However, the meaningful contribution from non-operating items (particularly FX gains) and inability to verify cash conversion limit the assessment to moderate quality pending full cash flow disclosure.
Full-year guidance: Revenue 158.0 billion yen, Operating Income 10.8 billion yen, Ordinary Income 12.1 billion yen, Net Income 7.5 billion yen.
Q3 cumulative progress rate vs. full-year guidance: Revenue 75.8% (119.7/158.0), Operating Income 82.6% (8.9/10.8), Ordinary Income 82.6% (10.0/12.1), Net Income 97.1% (7.3/7.5). Standard benchmark for Q3 is 75%.
Revenue progress of 75.8% is closely aligned with the 75% benchmark, indicating on-track performance. Operating income and ordinary income at 82.6% are ahead of the 75% benchmark by 7.6 points, suggesting strong profitability execution or conservative initial guidance. Net income progress of 97.1% is substantially ahead of benchmark by 22.1 points.
The advanced net income progress (97.1%) compared to operating income (82.6%) indicates Q4 forecast assumes lower profitability in the final quarter. Presentation materials show Q4 operating income forecast of 1.9 billion yen (+7.4% YoY), which would represent significant step-down from Q1-Q3 quarterly average of approximately 3.0 billion yen. This likely reflects seasonal patterns, planned investment expenses, or conservative planning.
No formal guidance revisions were announced during Q3. The company is maintaining its full-year targets despite exceeding interim benchmarks, suggesting management confidence in achieving targets while possibly building buffer for Q4 uncertainties including continued Wellness segment investment costs and Environmental Solutions segment challenges.
The strong progress rates, particularly in profitability metrics, position the company favorably to meet or potentially exceed full-year guidance absent material Q4 headwinds.
Dividend Policy: The company plans total annual dividend of 36 yen per share (interim 18 yen + year-end 18 yen) for FY2025. Based on forecast net income of 7.5 billion yen and estimated shares outstanding, the payout ratio targets approximately 40% based on presentation materials, which aligns with management's stated guideline of 40% payout ratio.
Based on actual Q3 cumulative net income of 7.3 billion yen and planned annual dividend of 36 yen per share, the implied payout ratio is approximately 40-45%, within sustainable range. This contrasts with XBRL calculation anomalies that suggested 153.8% payout ratio, which appears to stem from data normalization issues rather than actual policy.
Share Buyback: The company resolved a share buyback program in November 2025 with maximum acquisition of 1.82 million shares or 2.0 billion yen, executable through June 2026. As of January 2026, the company had acquired 813,200 shares. This represents proactive capital return alongside stable dividends.
Total Return Ratio: Management targets total return ratio of 74.7% for FY2025, combining the 40% dividend payout ratio with share buyback allocation. This elevated total return ratio demonstrates commitment to shareholder returns while maintaining sufficient internal retention for growth investments.
Sustainability Assessment: The 40% dividend payout ratio is sustainable and aligns with industry best practices. The company maintains strong cash position (16.9 billion yen cash vs. 9.0 billion yen debt) and adequate equity ratio (65.1%), providing capacity for both dividends and buybacks. However, ongoing significant capital investments (18.9 billion yen CapEx forecast) and extended receivables collection warrant monitoring of free cash flow generation to ensure both investment needs and shareholder returns remain balanced.
The dual-track approach of stable dividends (40% payout) plus opportunistic buybacks (total return ratio 74.7%) balances shareholder returns with reinvestment in growth initiatives, particularly the Wellness segment capacity expansion.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 6.4% exceeds industry median of 5.0% (manufacturing sector, 2025-Q3, n=98 companies), positioning ZACROS in the upper half of peer profitability. Operating Margin 7.5% falls below industry median of 8.3%, indicating room for improvement in operational efficiency relative to peers despite year-over-year margin expansion. Net Profit Margin 6.1% slightly below industry median of 6.3%, suggesting near-peer profitability after tax effects.
Efficiency: Asset Turnover 0.763 exceeds industry median of 0.58, indicating superior asset utilization and capital efficiency relative to manufacturing peers. Financial Leverage 1.54x aligns closely with industry median of 1.53, reflecting comparable capital structure conservatism.
Financial Health: Equity Ratio 65.1% exceeds industry median of 63.8%, demonstrating above-median financial stability and lower leverage risk. Current Ratio 194.2% falls below industry median of 284%, though remains adequate for liquidity needs; the lower ratio may reflect more efficient working capital management or industry-specific operating characteristics.
Growth: Revenue Growth YoY 5.6% exceeds industry median of 2.7%, positioning ZACROS in the upper quartile of revenue expansion among manufacturing peers (IQR: -1.9% to 7.9%).
Working Capital: Receivables Turnover 117 days exceeds industry median of 82.87 days by 34 days, indicating slower collection and potential working capital efficiency concerns relative to peers. This extended collection period represents an area warranting improvement to industry standard levels.
Overall Industry Position: ZACROS demonstrates above-median performance in asset efficiency, revenue growth, and ROE, with financial health metrics aligned with or exceeding peer standards. Operating margin represents the primary gap vs. peers, while extended receivables collection cycle indicates working capital management opportunity. The company's 6.4% ROE and 5.6% revenue growth position it favorably within the manufacturing sector reference group.
Industry: Manufacturing sector, Comparison: 2025-Q3 cross-sectional peer data, Source: Proprietary analysis
Wellness Segment Profitability Pressure: Ongoing depreciation burden of approximately 1.9 billion yen annually from new Mie facility combined with continued upfront investment costs for bioprocessing single-use bag development and commercialization. Current segment operating margin of 0.8% (compressed from historical levels) creates near-term earnings drag of approximately 0.6-0.8 billion yen quarterly vs. normalized levels. Risk materializes if bioprocessing bag commercialization timeline extends beyond current plans or market adoption disappoints, prolonging margin compression. Priority: High. Probability: Medium (timeline uncertainty inherent in new product launches).
Working Capital and Cash Conversion: Accounts receivable collection period of 117 days substantially exceeds industry median of 83 days, representing 34-day gap that ties up approximately 11 billion yen in incremental working capital vs. industry standard. Extended collection combined with significant construction in progress (14.5 billion yen, 9.2% of assets) creates cash flow pressure despite net cash balance sheet position. Risk intensifies if collection periods extend further or construction projects face delays, constraining available cash for dividends (3.6 billion yen annual commitment) and buybacks (up to 2.0 billion yen authorized). Priority: High. Probability: Medium-High given current DSO trends.
US Subsidiary Profitability in Environmental Solutions: Persistent underperformance at US liquid container subsidiary has prevented segment operating profit growth despite revenue expansion, with segment margin of 4.3% below other segments. Management has indicated customer delivery format changes and market conditions as headwinds. Continued weakness risks further margin erosion in Environmental Solutions (12% of total segment operating profit) and could require restructuring costs or asset impairments. Impact quantified at approximately 0.1-0.2 billion yen quarterly margin opportunity if subsidiary returns to profitability. Priority: Medium. Probability: Medium (turnaround timeline uncertain, external market dependent).
Short-term Refinancing and Liquidity Management: Short-term borrowings increased 693% YoY to 4.8 billion yen, elevating short-term debt ratio to 52.7% of total liabilities. While current ratio remains healthy at 194% and net cash position exists (16.9 billion yen cash vs. 9.0 billion yen total interest-bearing debt), the sharp increase in short-term debt concentration creates refinancing risk if credit conditions tighten or operating cash flow disappoints. Combined with extended receivables (117 days) and significant committed capital returns (dividends plus buybacks totaling approximately 5-6 billion yen), any deterioration in operating cash generation could stress liquidity. Priority: Medium-High. Probability: Low-Medium (manageable given current balance sheet strength but trend warrants monitoring).
Non-Operating Income Dependency: Ordinary income growth of 16.4% significantly exceeded operating income growth of 6.6%, with approximately 1.1 billion yen contribution from non-operating items (FX gains and interest income). While representing less than 1% of revenue, this contribution is inherently volatile and non-recurring. FX rate reversals or interest rate changes could eliminate this 1.1 billion yen annual benefit, reducing ordinary income by approximately 11% from current levels. This would pressure ability to meet ordinary income guidance (12.1 billion yen) if operating performance doesn't strengthen. Priority: Medium. Probability: Medium-High (FX and rates inherently volatile).
Capital Allocation Sustainability: Committed total return ratio of 74.7% (40% dividend payout + buybacks) combined with capital investment forecast of 18.9 billion yen requires robust free cash flow generation. Without disclosed operating cash flow data, sustainability assessment is limited. The combination of high total returns, significant CapEx, extended working capital (117-day receivables), and construction in progress buildup (14.5 billion yen) creates potential FCF constraint. If operating cash generation disappoints or working capital deteriorates further, the company may need to moderate buyback program or rely on existing cash reserves. Priority: Medium. Probability: Medium (dependent on undisclosed cash flow performance).
Profitability Inflection Driven by Industrial Infrastructure and Electronic Materials: The company demonstrated accelerating profit growth with operating income +6.6% exceeding revenue growth of +5.6%, driven by margin expansion in Industrial Infrastructure (12.7% margin, operating profit +17.6%) and Electronic Materials (8.8% margin, operating profit +12.2%). Industrial Infrastructure has emerged as the core profit contributor at 44% of segment operating profit despite representing only 27% of revenue, capitalizing on favorable construction markets and high-margin chemical products. Electronic Materials is capturing structural AI-semiconductor demand with information recording materials showing significant growth. These two segments generated 86% of segment operating profit growth and demonstrate sustainable competitive positioning. However, overall operating margin of 7.5% remains below industry median of 8.3%, indicating further margin improvement opportunity as Wellness segment normalizes and operating leverage continues. The 16.4% ordinary income growth outpaced operating income growth due to 1.1 billion yen in non-operating items (FX gains, interest income), which are inherently volatile and should not be extrapolated as recurring.
Wellness Segment Investment Cycle with Multi-Year Payoff Timeline: Wellness segment operating margin compressed to 0.8% from historical levels due to 1.9 billion yen annual depreciation from new Mie facility and upfront commercialization investment in bioprocessing single-use bags. This represents deliberate near-term profit sacrifice for long-term market position in high-growth bioprocessing consumables market. The segment's profit contribution has declined from approximately 0.6 billion yen quarterly to 0.2 billion yen, creating 0.4 billion yen quarterly earnings drag vs. normalized levels. Management's continued investment signals confidence in commercialization timeline and market opportunity, but represents 1-2 year profitability headwind. Recovery trajectory depends on bioprocessing bag order conversion and production scale-up to absorb fixed depreciation costs. This segment-specific investment cycle creates asymmetric risk-reward profile with near-term earnings visibility limited but potential for margin recovery to mid-single-digits as revenue scales over 2-3 year horizon.
Balance Sheet Strength with Working Capital Efficiency Gap: The company maintains robust financial health with 65.1% equity ratio (exceeding 63.8% industry median), net cash position of approximately 7.9 billion yen, and interest coverage of 58.7x. However, working capital management shows material gap vs. peers with accounts receivable days of 117 vs. industry median 83, tying up approximately 11 billion yen in excess working capital. Construction in progress of 14.5 billion yen (9.2% of assets) represents deployed capital awaiting conversion to productive assets. The combination of extended receivables, CIP buildup, and short-term borrowing increase (+693% YoY to 4.8 billion yen) alongside committed capital returns (74.7% total return ratio including 2.0 billion yen buyback program) creates cash flow management complexity. While current liquidity remains adequate, absence of operating cash flow disclosure limits visibility into sustainable free cash flow generation. The extended collection cycle and capital intensity create working capital optimization opportunity that could release meaningful cash if receivables days compress toward industry median.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
ZACROS Co., Ltd.’s Q3 FY2026 (fiscal year ending March 2026) results delivered higher revenue and profit, with net sales of 1,196億円 (+5.6% YoY) and operating profit of 89億円 (+6.6%). The full-year outlook also projects higher revenue and profit, with net sales of 1,580億円 and operating profit of 108億円. By segment, the Information Electronics business posted significant increases in both revenue and profit on the back of growth in the semiconductor market, while the Industrial Infrastructure business remained strong. In contrast, the Wellness business recorded a sharp profit decline due to increased depreciation stemming from capital investment in bio-related operations and upfront investments. The Environmental Solutions business was impacted by deteriorating profitability at the U.S. subsidiary. Company-wide, ordinary profit improved significantly to 99億円 (+16.4%), driven by contributions from non-operating income. A share repurchase program (up to 182万株 or 20億円) was resolved on November 6, 2025, with a total payout ratio expected at 74.7%.
Bio-related single-use bags (BioPhaS®) achieved revenue growth in Q3 amid expanding demand. Information recording materials in the Information Electronics business saw a significant YoY revenue increase due to growth in the semiconductor market for AI. Building materials within the Industrial Infrastructure business (air-conditioning piping, void slab, and building chimneys) performed strongly. Depreciation increased by 4億円 YoY to 14億円 due to the commencement of operations at the new building of the Mie site. Profit in the Environmental Solutions business was pressured by deteriorating profitability at the U.S. liquid container subsidiary.
For the full year, the Information Electronics business is expected to achieve higher revenue and profit, supported by growth in the semiconductor market for AI. The Industrial Infrastructure business is projected to increase profit on solid orders for chimney construction and higher sales in chemical products. The Environmental Solutions business aims to secure profit growth through price pass-throughs and a reconfiguration of order mix. The Wellness business is expected to see profit decline due to increased depreciation (19億円) from strengthening bio-related production capacity and the continuation of development and human capital investments, although pharmaceuticals and medical-related operations are expected to increase revenue by securing orders both domestically and internationally.
For FY2025 full year, the company forecasts higher revenue and profit, with net sales of 1,580億円 (+4.8%), operating profit of 108億円 (+6.8%), ordinary profit of 121億円 (+16.7%), and net income of 75億円 (+14.8%). Dividends are planned at 18円 interim and 18円 year-end, totaling 36円 annually. The total payout ratio, including share repurchases, is expected to be 74.7%. In bio-related operations, the company plans to capture steadily rising demand to drive revenue growth, though upfront investment burdens are expected to weigh on profits in the short term.
Upfront spending and strengthening of the production framework to expand sales of single-use bags for biopharmaceutical manufacturing (BioPhaS®). Full-scale operation of the new building at the Mie site to expand production capacity in the Wellness business. Revenue growth strategy for information recording materials in the Information Electronics business by capturing growth in the semiconductor market for AI. Profitability improvement in the Environmental Solutions business through promotion of order mix reconfiguration. Operational efficiency and fixed cost control in the Industrial Infrastructure business through core system upgrades.
Sluggish sales and deteriorating profitability at the U.S. liquid container subsidiary. Profitability deterioration due to stagnant production at the Taiwan display-related subsidiary. Short-term profit pressure from upfront fixed costs and development investment in bio-related operations. Increase in fixed costs centered on personnel expenses and the impact of higher material prices, etc. Revenue impact in the U.S. liquid container business due to changes in delivery formats to customers.